Pre-made Mibavademab biosimilar (Whole mAb, anti-LEPR therapeutic antibody, Anti-CD295/LEPRD/OB-R/OBR Antibody) - benchmark reference antibody
Cat:GMP-Bios-ab-343
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Mibavademab biosimilar (Whole mAb, anti-LEPR therapeutic antibody, Anti-CD295/LEPRD/OB-R/OBR Antibody) – benchmark reference antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
| Products Name (INN Index) | Pre-Made Mibavademab biosimilar, Whole mAb, Anti-LEPR Antibody: Anti-CD295/OB-R/OBR therapeutic antibody |
|---|---|
| INN Name | Mibavademab |
| Target | LEPR |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Lipodystrophy |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LEPR |
| Package |
Previous slide
Next slide
